Shilpa Medicare update on USFDA inspection of facility at Jadcherla, Telangana

Image
Capital Market
Last Updated : Dec 06 2017 | 10:16 AM IST

Receives 10 observations under Form 483

Shilpa Medicare has received 483 Observations from the United States Food & Drug Administration (USFDA) in relation to SEZ Formulation Facilities situated at Jadcherla, Telangana (near Hyderabad) as under;

a) Total 10 observations were cited during the close up meeting.
b) 7 observations are improvement in procedures and practices.
c) 3 observations are related to setting of analytical specifications, test procedures and method validation.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Dec 06 2017 | 9:57 AM IST

Next Story